Cell population including mesenchymal stem cells and production method therefor, and pharmaceutical composition
An object of the present invention is to provide a cell population comprising mesenchymal cells having low cell aggregability, which is useful for intravenous administration of a cell preparation, and a method for producing the same, and a pharmaceutical composition comprising the cell population. Also provided are methods for producing a cell population comprising mesenchymal stem cells, the method comprising obtaining a cell population having the following cell characteristics (the cell population satisfies the relative expression level of COL11A1 gene to the expression level of SDHA gene of 6.0 or less and the relative expression level of COL16A1 gene to the expression level of SDHA gene of 1.5 or less).
1. A cell population comprising mesenchymal stem cells, the cell population having the following cell characteristics: the cell population satisfies the relative expression level of COL11A1 gene to the expression level of SDHA gene of 6.0 or less and the relative expression level of COL16A1 gene to the expression level of SDHA gene of 1.5 or less.
2. The cell population of claim 1 , wherein the cell population is a cultured or cryopreserved cell population.
3. The cell population of claim 1 , wherein the cell population further has the following cell characteristics: the cell population satisfies the relative expression level of COL4A5 gene to the expression level of SDHA gene of 0.4 or less.
4. The cell population of claim 1 , wherein the cell population further has the following cell characteristics: the cell population satisfies any one or more of: the relative expression level of VCAN gene to the expression level of SDHA gene of 6.0 or less; the relative expression level of DCN gene to the expression level of SDHA gene of 3.0 or less; and the relative expression level of LUM gene to the expression level of SDHA gene of 6.0 or less.
5. The cell population of claim 1 , wherein the cell population further has the following cell characteristics: the cell population satisfies the relative expression level of GPC4 gene to the expression level of SDHA gene of 0.5 or less.
6. The cell population of claim 1 , wherein the proportion of CDH6-positive mesenchymal stem cells is 30% or more in the cell population.
7. The cell population of claim 1 , wherein the mesenchymal stem cells are derived from a fetal appendage.
8. The cell population of claim 1 , wherein the cell population has a low cell aggregability.
9. The cell population of claim 1 , wherein the cell population can be cultured up to 40 days or later after start of an in vitro culture.
10. A pharmaceutical composition comprising the cell population of claim 1 , and a pharmaceutically acceptable vehicle.